AIM ImmunoTech Management
Management criteria checks 3/4
AIM ImmunoTech's CEO is Thomas Equels, appointed in Aug 2015, has a tenure of 9.25 years. total yearly compensation is $1.08M, comprised of 78.6% salary and 21.4% bonuses, including company stock and options. directly owns 2.36% of the company’s shares, worth $318.00K. The average tenure of the management team and the board of directors is 8.7 years and 8.3 years respectively.
Key information
Thomas Equels
Chief executive officer
US$1.1m
Total compensation
| CEO salary percentage | 78.6% |
| CEO tenure | 9.3yrs |
| CEO ownership | 2.4% |
| Management average tenure | 8.7yrs |
| Board average tenure | 8.3yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$24m |
| Jun 30 2024 | n/a | n/a | -US$28m |
| Mar 31 2024 | n/a | n/a | -US$31m |
| Dec 31 2023 | US$1m | US$850k | -US$29m |
| Sep 30 2023 | n/a | n/a | -US$21m |
| Jun 30 2023 | n/a | n/a | -US$19m |
| Mar 31 2023 | n/a | n/a | -US$19m |
| Dec 31 2022 | US$1m | US$850k | -US$19m |
| Sep 30 2022 | n/a | n/a | -US$21m |
| Jun 30 2022 | n/a | n/a | -US$18m |
| Mar 31 2022 | n/a | n/a | -US$19m |
| Dec 31 2021 | US$2m | US$850k | -US$19m |
| Sep 30 2021 | n/a | n/a | -US$17m |
| Jun 30 2021 | n/a | n/a | -US$17m |
| Mar 31 2021 | n/a | n/a | -US$14m |
| Dec 31 2020 | US$3m | US$807k | -US$14m |
| Sep 30 2020 | n/a | n/a | -US$12m |
| Jun 30 2020 | n/a | n/a | -US$11m |
| Mar 31 2020 | n/a | n/a | -US$10m |
| Dec 31 2019 | US$890k | US$703k | -US$9m |
| Sep 30 2019 | n/a | n/a | -US$10m |
| Jun 30 2019 | n/a | n/a | -US$10m |
| Mar 31 2019 | n/a | n/a | -US$10m |
| Dec 31 2018 | US$1m | US$751k | -US$10m |
| Sep 30 2018 | n/a | n/a | -US$10m |
| Jun 30 2018 | n/a | n/a | -US$8m |
| Mar 31 2018 | n/a | n/a | -US$8m |
| Dec 31 2017 | US$987k | US$713k | -US$8m |
Compensation vs Market: Thomas's total compensation ($USD1.08M) is above average for companies of similar size in the US market ($USD652.28K).
Compensation vs Earnings: Thomas's compensation has been consistent with company performance over the past year.
CEO
Thomas Equels (71 yo)
9.3yrs
Tenure
US$1,081,301
Compensation
Mr. Thomas K. Equels, Esq. M.S., J.D. serves as Director at BioFlorida Inc since August 2021. He serves as the Chief Executive Officer of AIM ImmunoTech Inc. (formerly known as Hemispherx Biopharma, Inc.)...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Vice Chairman | 9.3yrs | US$1.08m | 2.36% $ 318.0k | |
| Chief Financial Officer | 2.6yrs | US$64.48k | 0% $ 0 | |
| COO, Executive Director of Governmental Relations | 8.1yrs | US$527.64k | 0.63% $ 85.5k | |
| Scientific Officer | 1.9yrs | no data | no data | |
| Director of Administration & Human Resources and Deputy Investor Relations Coordinator | 11.8yrs | no data | no data | |
| Vice President of QC & Manufacturing | 14.6yrs | no data | no data |
8.7yrs
Average Tenure
70yo
Average Age
Experienced Management: AIM's management team is seasoned and experienced (8.7 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Vice Chairman | 16yrs | US$1.08m | 2.36% $ 318.0k | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Chairman of the Board & Member of Scientific Advisory Board | 26.3yrs | US$139.37k | 0.12% $ 16.3k | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 1.7yrs | US$93.75k | 0.061% $ 8.2k | |
| Independent Director | 8.3yrs | US$139.37k | 0.38% $ 51.1k | |
| Chairman of Scientific Advisory Board | 1.6yrs | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data |
8.3yrs
Average Tenure
70yo
Average Age
Experienced Board: AIM's board of directors are considered experienced (8.3 years average tenure).